{"url_path":"/sec/crnx/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1658247/0001658247-26-000044-index.html","accession_number":"0001658247-26-000044","cik":"0001658247","ticker":"CRNX","issuer_name":"Crinetics Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1658247/0001658247-26-000044-index.html","primary_entity_key":"0001658247","primary_entity_name":"Crinetics Pharmaceuticals, Inc."},"word_count":282,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nThe annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the “Company”) was held online via live audio webcast on June 18, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 102,030,415 shares of common stock, or approximately 97% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows:\n\nProposal One - Election of Directors\n\nThe Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were:\n\nVotes ForVotes WithheldBroker Non-Votes\n\nCaren Deardorf73,454,07623,532,3285,044,011\n\nWeston Nichols, Ph.D.90,208,5646,777,8405,044,011\n\nStephanie S. Okey, M.S.72,225,31324,761,0915,044,011\n\nProposal Two - Ratification of Selection of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were:\n\nVotes ForVotes AgainstAbstentions\n\n101,675,974341,72712,714\n\nProposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:\n\nVotes ForVotes AgainstAbstentionsBroker Non-Votes\n\n91,657,9922,698,5382,629,8745,044,011\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nCrinetics Pharmaceuticals, Inc.\n\nDate:\nJune 22, 2026\nBy:/s/ R. Scott Struthers, Ph.D.\n\nR. Scott Struthers, Ph.D.\nPresident and Chief Executive Officer\n(Principal Executive Officer)"}